Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | C.H. Boehringer Sohn AG and Co KG | 121 |
| 2 | Calcimedica Inc | 12 |
| 3 | Vertex Pharmaceuticals Inc | 10 |
| 4 | University of California | 8 |
| 5 | Children's Hospital of Philadelphia | 7 |
| 6 | Takeda Pharmaceutical Co Ltd | 5 |
| 7 | Labcorp Holdings Inc | 4 |
| 8 | Bruker Corp | 3 |
| 9 | Michigan State University | 2 |
| 10 | Novo Nordisk Fonden | 2 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 243 |
| 2 | C07D | Heterocyclic compounds | 213 |
| 3 | A61K | Medicinal preparations | 151 |
| 4 | G01N | Investigating / analysing materials | 60 |
| 5 | Y02A | Climate change adaptation | 43 |
| 6 | G16B | 17 | |
| 7 | C07K | Peptides | 16 |
| 8 | C12Q | Measuring/testing involving enzymes | 13 |
| 9 | C07J | 10 | |
| 10 | G16C | 10 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | 2010 | C.H. Boehringer Sohn AG and Co KG | 99 |
| CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | 2008 | C.H. Boehringer Sohn AG and Co KG | 101 |
| SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | 2010 | C.H. Boehringer Sohn AG and Co KG | 82 |
| Ubiquitin protease | 2009 | Takeda Pharmaceutical Co Ltd | 85 |
| 27411, a novel human PGP synthase | 2006 | Takeda Pharmaceutical Co Ltd | 92 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2017 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Alexei V. Tepikin | University of Liverpool | 10 |
| 2 | Robert Sutton | University of Liverpool | 7 |
| 3 | Dieter Häussinger | Heinrich Heine University Düsseldorf | 6 |
| 4 | Ole H. Petersen | University of Liverpool | 6 |
| 5 | David N. Criddle | University of Liverpool | 6 |
| 6 | Sohail Z. Husain | University of Pittsburgh | 5 |
| 7 | Oleg V. Gerasimenko | University of Liverpool | 5 |
| 8 | Svetlana Voronina | University of Liverpool | 5 |
| 9 | Roland Reinehr | Heinrich Heine University Düsseldorf | 5 |
| 10 | Dongbo Xue | Harbin Medical University | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| TLR9 and the NLRP3 Inflammasome Link Acinar Cell Death With Inflammation in Acute Pancreatitis | 2011 | 296 | Pancreatitis Pathology and Treatment |
| Biliary Acute Pancreatitis in Mice is Mediated by the G-Protein−Coupled Cell Surface Bile Acid Receptor Gpbar1 | 2009 | 123 | Protein Kinase Regulation and GTPase Signaling |
| Experimental acute biliary pancreatitis induced by retrograde infusion of bile acids into the mouse pancreatic duct | 2010 | 111 | Liver Disease Diagnosis and Treatment |
| Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase–dependent manner | 2002 | 96 | Cell death mechanisms and regulation |
| Prevention of bile acid-induced apoptosis by betaine in rat liver | 2002 | 84 | Liver Disease Diagnosis and Treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Taurolithocholic acid 3-sulfate?
Which organization holds the most patents related to this compound?
What research topics are most prominent in the patent landscape for this compound?
Who are the most prolific academic authors publishing on this compound?
What are the key research areas covered in published papers on this compound?